• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Divislab Share Price

    Divi's Laboratories Share PriceDivi's Laboratories

    Large Cap 68.8k Result
    ₹3,681.75
    -52.6 (-1.41%)
    • Advice
    • Hold
    As on 11 December, 2023 | 02:47 BSE: 532488 NSE: DIVISLABISIN: INE361B01024

    Divi's Laboratories Performance

    Day Range

    • Low 3,662.40
    • High 3,747.45
    ₹ 3,681.75

    52 Week Range

    • Low 2,730.00
    • High 3,934.70
    ₹ 3,681.75
    • Open Price3,739.00
    • Previous Close3,734.35
    • Volume455037

    Start SIP in Divi's Laboratories

    Start SIP

    Divi's Laboratories Share Price

    • Over 1 Month 5.47%
    • Over 3 Month -0.46%
    • Over 6 Month 5.2%
    • Over 1 Year 11.99%

    Divi's Laboratories Key Statistics

    P/E Ratio 73.4
    PEG Ratio -1.3
    Market Cap Cr 97,739
    Price to Book Ratio 7.7
    EPS 68.1
    Dividend 0.8
    Relative Strength Index 52.01
    Money Flow Index 69.92
    MACD Signal 48.3
    Average True Range 70.6

    Divi's Laboratories F&O

    Divi's Laboratories Futures
    Divi's Laboratories Option Chain

    Divi's Laboratories Investment Rating

    • Master Rating:

    • Divis Laboratories (Nse) has an operating revenue of Rs. 7,345.45 Cr. on a trailing 12-month basis. An annual revenue de-growth of -11% needs improvement, Pre-tax margin of 30% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 7% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Divi's Laboratories Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,8681,7301,9081,6901,8232,2042,495
    Operating Expenses Qtr Cr 1,3941,2391,4191,2801,2141,3661,399
    Operating Profit Qtr Cr 4744914894096098381,096
    Depreciation Qtr Cr 94938787858381
    Interest Qtr Cr 1000000
    Tax Qtr Cr 122133149128116152183
    Net Profit Qtr Cr 342345319311487692883
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 7,9748,991
    Operating Expenses Annual Cr 5,2785,003
    Operating Profit Annual in Cr 2,3483,876
    Depreciation Cr 342311
    Interest Annual Cr 11
    Tax Annual Cr 546728
    Net Profit Annual Cr 1,8082,949
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1,9101,910
    Cash from Investing Activity Annual Cr -2,195-2,195
    Cash from Financing Annual Activity Cr -532-532
    Net Cash Flow Annual Cr -817
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 12,70511,691
    Fixed Assets Annual Cr 4,9314,791
    Total Non Current Assets Annual Cr 5,1165,012
    Total Current Assets Annual Cr 9,2358,296
    Total Assets Annual Cr 14,35213,308
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 479440
    ROE Annual % 1425
    ROCE Annual % 1830
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3545
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,9091,7781,9511,7081,8552,2552,518
    Operating Expenses Qtr Cr 1,4301,2741,4631,2991,2341,4081,414
    Operating Profit Qtr Cr 4795044884086218471,104
    Depreciation Qtr Cr 95938787868481
    Interest Qtr Cr 1000000
    Tax Qtr Cr 121136146129122149181
    Net Profit Qtr Cr 348356321307494702895
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 8,1129,074
    Operating Expenses Annual Cr 5,4005,078
    Operating Profit Annual in Cr 2,3683,882
    Depreciation Cr 343312
    Interest Annual Cr 11
    Tax Annual Cr 545723
    Net Profit Annual Cr 1,8232,960
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1,9121,912
    Cash from Investing Activity Annual Cr -2,195-2,195
    Cash from Financing Annual Activity Cr -532-532
    Net Cash Flow Annual Cr -816
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 12,76711,728
    Fixed Assets Annual Cr 4,9344,795
    Total Non Current Assets Annual Cr 5,1275,023
    Total Current Assets Annual Cr 9,3128,352
    Total Assets Annual Cr 14,43913,375
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 481442
    ROE Annual % 1425
    ROCE Annual % 1830
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3545
    Invest in Divi's Laboratories

    Divi's Laboratories Technicals

    EMA & SMA

    Current Price
    ₹3,681.75
    -52.6 (-1.41%)
    pointer
    • Bullish Moving Average
    • ___
    • 10
    • Bearish Moving Average
    • ___
    • 6
    • 20 Day
    • ₹3,684.89
    • 50 Day
    • ₹3,643.52
    • 100 Day
    • ₹3,610.63
    • 200 Day
    • ₹3,561.81
    • 20 Day
    • ₹3,675.84
    • 50 Day
    • ₹3,618.67
    • 100 Day
    • ₹3,661.46
    • 200 Day
    • ₹3,440.73

    Divi's Laboratories Resistance and Support

    PIVOT
    ₹3,697.2
    Resistance
    First Resistance 3,732.00
    Second Resistance 3,782.25
    Third Resistance 3,817.05
    RSI 52.01
    MFI 69.92
    MACD Single Line 48.30
    MACD 47.83
    Support
    First Resistance 3,646.95
    Second Resistance 3,612.15
    Third Resistance 3,561.90

    Divi's Laboratories Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 461,356 26,551,038 57.55
    Week 369,078 22,358,745 60.58
    1 Month 406,281 18,339,503 45.14
    6 Month 445,556 17,251,930 38.72

    Divi's Laboratories Result Highlights

    Divi's Laboratories Synopsis

    NSE-Medical-Generic Drugs

    Divi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 7625.30 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2023. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
    Market Cap 97,739
    Sales 7,196
    Shares in Float 12.74
    No of funds 757
    Yield 0.81
    Book Value 7.69
    U/D Vol ratio 1.1
    LTDebt / Equity
    Alpha 0.04
    Beta 0.26

    Divi's Laboratories

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 51.93%51.93%51.94%51.94%
    Mutual Funds 13.62%13.2%13.15%12.68%
    Insurance Companies 7.17%6.91%6.78%6.76%
    Foreign Portfolio Investors 14.6%14.69%14.67%15.15%
    Financial Institutions/ Banks 0.18%0.12%0.11%0.12%
    Individual Investors 9.02%9.27%9.61%9.52%
    Others 3.48%3.88%3.74%3.83%

    Divi's Laboratories Management

    Name Designation
    Dr. Ramesh B V Nimmagadda Non Exe.Chairman&Ind.Director
    Dr. Murali K Divi Managing Director
    Dr. Kiran S Divi WholeTime Director & CEO
    Ms. Nilima Prasad Divi Whole Time Director
    Mr. Madhusudana Rao Divi Whole Time Director
    Mr. N V Ramana Executive Director
    Mr. K V K Seshavataram Independent Director
    Dr. G Suresh Kumar Independent Director
    Mr. R Ranga Rao Independent Director
    Prof. Sunaina Singh Independent Director
    Dr. S Ganapaty Independent Director
    Mr. K V Chowdary Independent Director

    Divi's Laboratories Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Divi's Laboratories Corporate Action

    Date Purpose Remarks
    2023-11-06 Quarterly Results
    2023-08-14 Quarterly Results
    2023-05-20 Audited Results & Final Dividend
    2023-02-03 Quarterly Results
    2022-11-07 Quarterly Results
    Date Purpose Remarks
    2023-08-11 FINAL Rs.30.00 per share(1500%)Final Dividend
    2022-08-12 FINAL Rs.30.00 per share(1500%)Dividend

    Divi's Laboratories MF Shareholding

    Name Amount(cr)
    SBI Nifty 50 ETF 155,471
    HDFC Balanced Advantage Fund Growth 63,981
    SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl 59,302
    UTI Nifty 50 Exchange Traded Fund 42,363
    SBI Bluechip Fund Regular Growth 38,598

    About Divi's Laboratories

    Established in 1990, the Indian multinational pharmaceuticals company Divis Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs)including generic APIs, Nutraceutical Ingredients, and Custom Synthesis of the APIs providing high-quality products to over 95 countries. It is headquartered in Hyderabad, Telangana, India.

    Divis Laboratories is among the world's leading manufacturers of generic APIs, offering a competitive advantage over the entire life cycle of the products. Competent in handling high-potency, high-energy reactions to fulfil the unmet needs of the big pharma customers, Divis Laboratories is the second most valuable pharmaceutical firm in India by market value.

    In 1990, Divis Laboratories was founded as Divis Research Centre. Initially, the company began developing commercial techniques for the production of APIs and intermediates. In 1994, Divis Research Centre rebranded as Divis Laboratories Limited to indicate its entry into the API and intermediates manufacturing industry.

    1997: The United Kingdom's SGS–Yarsley certifies Divis Laboratories as ISO–9002 compliant.
    1999: The European Directorate issues a Certificate of Suitability (CoS) for the Naproxen manufactured by Divis Laboratories.
    2001: London's BVQI grants Divis OHSAS–18001 Certification (for its Occupational Health and Safety Management Systems).
    2003: Divis inaugurates a new research centre dubbed "DRC–Vizag".
    2003: Went for IPO and was listed on the BSE, NSE, and HSE stock markets.
    2007: Set up Nutraceuticals facility at Unit 2
    2008: The third US-FDA examination of Choutuppal(Unit-1).
    2008: The Visakhapatnam(Unit–2) is inspected by the KFDA.
    2010: Letter of approval received by Divis Laboratories for the establishment and development of a new pharmaceutical ingredient manufacturing unit in SEZ at Visakhapatnam.
    2016: First Anvisa (Brazil) inspection
    2020: 8th USFDA inspection at unit 2.

    Shareholding Pattern

    In addition, public holdings account for 11.3% of the company's equity. The company's equity is held by retail and other investors to the tune of 4.6%.

    Corporate Social Responsibility

    Corporate Social Responsibility at Divis Laboratories consists of social programs, community service, and environmental impact awareness. Some key initiatives are mentioned below.

    Child Empowerment Initiatives- 

    Promoting Education
    Preventive Healthcare
    Empowering Women
    Safe Drinking water
    Swaach Bharat

    Healthcare Initiatives-

    Free Eye and Dental care Camps
    ORT training and pulse polio campaigns
    Incentives for Family Planning and awareness campaigns on HIV/ Aids, epidemics and malaria

    Initiatives for Development of Village-

    Laying of CC Roads in Villages
    Construction of underground Drainages in Villages
    Construction of Overhead Tanks
    Laying of Gravel Roads from villages to Agricultural Fields
    Facilitate Street lights in Villages


    FINANCIAL INFORMATION

    Bottom Line

    The profit recorded has grown exponentially from INR 1219 crore to INR 3676 crore in 5 yrs. This is due to a substantial rise in revenue and a decrease in selling, general, and administrative costs.

    Net Worth

    It has grown by a whopping INR 5668.59 crore over the last 5 yrs.

     

    Divi's Laboratories FAQs

    What is Share Price of Divi's Laboratories ?

    Divi's Laboratories share price is ₹3,681 As on 11 December, 2023 | 02:33

    What is the Market Cap of Divi's Laboratories ?

    The Market Cap of Divi's Laboratories is ₹97738.9 Cr As on 11 December, 2023 | 02:33

    What is the P/E ratio of Divi's Laboratories ?

    The P/E ratio of Divi's Laboratories is 73.4 As on 11 December, 2023 | 02:33

    What is the PB ratio of Divi's Laboratories ?

    The PB ratio of Divi's Laboratories is 7.7 As on 11 December, 2023 | 02:33

    What does Divis Laboratories do?

    Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.

    Is Divis Laboratories good for the long term?

    Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.

    Is Divis Laboratories debt-free?

    Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

    Who is the owner of Divis Laboratories?

    Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).

    How to buy Divis Laboratory?

    You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.